<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949662</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0345</org_study_id>
    <secondary_id>NCI-2013-02351</secondary_id>
    <secondary_id>1R21CA186000-01A1</secondary_id>
    <nct_id>NCT01949662</nct_id>
  </id_info>
  <brief_title>Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer</brief_title>
  <official_title>A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if giving lorazepam in combination with&#xD;
      haloperidol can help to control the symptoms of delirium in patients with advanced cancer.&#xD;
      The safety of this drug combination will also be studied.&#xD;
&#xD;
      In this study, lorazepam is being compared to a placebo. A placebo is not a drug. It looks&#xD;
      like the study drug but is not designed to treat any disease or illness. It is designed to be&#xD;
      compared with a study drug to learn if the study drug has any real effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the flip of a coin) to 1 of 2 study groups:&#xD;
&#xD;
        -  If you are in Group 1, you will receive lorazepam.&#xD;
&#xD;
        -  If you are in Group 2, you will receive a placebo.&#xD;
&#xD;
      Neither you nor the study staff will know if you are receiving the study drug or the placebo.&#xD;
      However, if needed for your safety, the study staff will be able to find out what you are&#xD;
      receiving. You will have an equal chance of being in each group.&#xD;
&#xD;
      All patients will receive haloperidol as part of your standard of care. The study doctor can&#xD;
      tell you more about haloperidol, how it is designed to work, and about any side effects it&#xD;
      may have.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      After you have started receiving haloperidol, you will receive lorazepam or the placebo by&#xD;
      vein 1 time over about 1-2 minutes.&#xD;
&#xD;
      Study Tests:&#xD;
&#xD;
      Every day while you are in the palliative care unit, you will be asked to complete the same&#xD;
      questionnaires about symptoms and how you are feeling that you were asked at screening. If at&#xD;
      any point you recover from your confusion, you will be asked if you remember the confusion&#xD;
      and how distressing it was.&#xD;
&#xD;
      Saliva Samples:&#xD;
&#xD;
      While you are in the hospital, saliva samples (about 1/2 a teaspoon) will be collected every&#xD;
      day to check for changes in your body's chemical levels. To collect the saliva, a swab will&#xD;
      be brushed inside your mouth until enough saliva is gathered on the swab. This should take&#xD;
      about 30 seconds to complete.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will receive the study drug or placebo 1 time. You will be monitored as part of this&#xD;
      study until you leave the palliative care unit. You may go off study at any time that&#xD;
      you/your caregiver decides it is in your best interest.&#xD;
&#xD;
      This is an investigational study. Lorazepam is FDA approved and commercially available for&#xD;
      the treatment of anxiety, insomnia, and seizures. Its use to help control agitation/delirium&#xD;
      is investigational.&#xD;
&#xD;
      Up to 60 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points</measure>
    <time_frame>Baseline to 8 hours</time_frame>
    <description>The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points</measure>
    <time_frame>8 hours</time_frame>
    <description>Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Richmond Agitation-Sedation Scale Score From Baseline to 30 Min</measure>
    <time_frame>Baseline to 30 minutes</time_frame>
    <description>Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Richmond Agitation-Sedation Scale Score &gt;=1 Within 8 hr</measure>
    <time_frame>Baseline to 8 hours</time_frame>
    <description>Number of participants with Richmond Agitation-Sedation Scale score &gt;=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Lorazepam + Haloperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>3 mg by vein one time only.</description>
    <arm_group_label>Lorazepam + Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consisting of preservative free 0.9% normal saline given one time by vein.</description>
    <arm_group_label>Placebo + Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol decanoate</intervention_name>
    <description>8 mg/day by vein.</description>
    <arm_group_label>Lorazepam + Haloperidol</arm_group_label>
    <arm_group_label>Placebo + Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.</description>
    <arm_group_label>Lorazepam + Haloperidol</arm_group_label>
    <arm_group_label>Placebo + Haloperidol</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. [Patients] Diagnosis of advanced cancer (defined as locally advanced, metastatic,&#xD;
             recurrent, or incurable disease)&#xD;
&#xD;
          2. [Patients] Admitted to Acute Palliative Care Unit (APCU)&#xD;
&#xD;
          3. [Patients] Delirium as per the Diagnostic and Statistical Manual of Mental Disorders&#xD;
             (DSM-IV-TR) criteria&#xD;
&#xD;
          4. [Patients] Hyperactive/mixed delirium with RASS &gt;/=2 in the last 24 hours&#xD;
&#xD;
          5. [Patients] On scheduled haloperidol of &lt;/=8 mg in the last 24 hours&#xD;
&#xD;
          6. [Patients] Age 18 or older&#xD;
&#xD;
          7. [Patients] Legally Authorized Representative consent&#xD;
&#xD;
          8. [Family Caregivers] Patient's spouse, adult child, sibling, parent, other relative, or&#xD;
             significant other (defined by the patient as a partner)&#xD;
&#xD;
          9. [Family Caregivers] Age 18 or older&#xD;
&#xD;
         10. [Family Caregivers] At the patient's bedside at least 4 hours each day during patient&#xD;
             delirium episode&#xD;
&#xD;
         11. [Patients and Family Caregivers] Able to communicate in English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. [Patients] History of myasthenia gravis or acute narrow angle glaucoma&#xD;
&#xD;
          2. [Patients] History of neuroleptic malignant syndrome&#xD;
&#xD;
          3. [Patients] History of Parkinson's disease or dementia&#xD;
&#xD;
          4. [Patients] Uncontrolled seizure disorder&#xD;
&#xD;
          5. [Patients] History of hypersensitivity to haloperidol or benzodiazepine&#xD;
&#xD;
          6. [Patients] On regular doses of benzodiazepine or chlorpromazine within the past 48&#xD;
             hours&#xD;
&#xD;
          7. [Patients] Previously documented and persistent QTc prolongation (&gt;500 ms)&#xD;
&#xD;
          8. [Patients] Heart failure exacerbation at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>Locally advanced cancer</keyword>
  <keyword>Metastatic cancer</keyword>
  <keyword>Recurrent cancer</keyword>
  <keyword>Incurable cancer</keyword>
  <keyword>Delirium</keyword>
  <keyword>Agitation</keyword>
  <keyword>Lorazepam</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Placebo</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <keyword>Acute palliative care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between 1/2014 and 6/2016 from MD Anderson Cancer Center with active cancer diagnosis, having age &gt;=18, with Delirium with Richmond Agitation-Sedation Scale score of &gt;=2 and receiving scheduled Haloperidol 1-8 mg/day.</recruitment_details>
      <pre_assignment_details>3 patients were excluded before randomization. 1 died and 2 were ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
          <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
        </group>
        <group group_id="P2">
          <title>Control Group (Placebo &amp; Haloperidol)</title>
          <description>Received single dose of Haloperidol (2mg IV, once)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged before an agitation event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropped out</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat analysis of 58 participants, 29 for each arm</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
          <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
        </group>
        <group group_id="B2">
          <title>Control Group (Placebo &amp; Haloperidol)</title>
          <description>Received single dose of Haloperidol (2mg IV, once)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="43" upper_limit="90"/>
                    <measurement group_id="B2" value="64" lower_limit="30" upper_limit="88"/>
                    <measurement group_id="B3" value="65" lower_limit="30" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High School or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed College</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Metastatic Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent or Persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>GastroIntestinal Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematological Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gynecological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky performance status</title>
          <description>The Karnofsky Performance Status scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points</title>
        <description>The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
        <time_frame>Baseline to 8 hours</time_frame>
        <population>Intent to treat 58 participants, a total of 29 for each arm; 3 participants were lost to follow up from each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
            <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Placebo &amp; Haloperidol)</title>
            <description>Received single dose of Haloperidol (2mg IV, once)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points</title>
          <description>The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
          <population>Intent to treat 58 participants, a total of 29 for each arm; 3 participants were lost to follow up from each arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" lower_limit="-4.8" upper_limit="-3.4"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-2.9" upper_limit="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points</title>
        <description>Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
        <time_frame>8 hours</time_frame>
        <population>Intent to treat 58 participants, a total of 29 for each arm; 3 participants were lost to follow up from each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
            <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Placebo &amp; Haloperidol)</title>
            <description>Received single dose of Haloperidol (2mg IV, once)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points</title>
          <description>Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
          <population>Intent to treat 58 participants, a total of 29 for each arm; 3 participants were lost to follow up from each arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.2" upper_limit="-1.9"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.3" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Richmond Agitation-Sedation Scale Score From Baseline to 30 Min</title>
        <description>Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
        <time_frame>Baseline to 30 minutes</time_frame>
        <population>Intent to treat 58 participants, a total of 29 for each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
            <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Placebo &amp; Haloperidol)</title>
            <description>Received single dose of Haloperidol (2mg IV, once)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Richmond Agitation-Sedation Scale Score From Baseline to 30 Min</title>
          <description>Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
          <population>Intent to treat 58 participants, a total of 29 for each arm</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-4.3" upper_limit="-2.9"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-2.2" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Richmond Agitation-Sedation Scale Score &gt;=1 Within 8 hr</title>
        <description>Number of participants with Richmond Agitation-Sedation Scale score &gt;=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
        <time_frame>Baseline to 8 hours</time_frame>
        <population>Intent to treat 58 participants, a total of 29 from each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
            <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Placebo &amp; Haloperidol)</title>
            <description>Received single dose of Haloperidol (2mg IV, once)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Richmond Agitation-Sedation Scale Score &gt;=1 Within 8 hr</title>
          <description>Number of participants with Richmond Agitation-Sedation Scale score &gt;=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.</description>
          <population>Intent to treat 58 participants, a total of 29 from each arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 3 days</time_frame>
      <desc>UKU (Udvalg for Kliniske Unders√∏gelser ) Adverse events Assessment. Total intent to treat = 58 (29+29); Total Participants used for the All Cause Mortality in both Arms, Intervention (47), and Placebo (43). The total number of deaths in the Intervention Group were 10 which includes 9 from the incomplete category and 1 from the complete category. The total number of deaths in the Control Group were 10 which includes 7 from the incomplete category and 3 from the complete category.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group (Lorazepam &amp; Haloperidol)</title>
          <description>Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)</description>
        </group>
        <group group_id="E2">
          <title>Control Group (Placebo &amp; Haloperidol)</title>
          <description>Received single dose of Haloperidol (2mg IV, once)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Hui, MD/ Associate Professor, Palliative Care Medicine</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-6258</phone>
      <email>dhui@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

